Immunological tolerance and function: Associations between intestinal bacteria, probiotics, prebiotics, and phages

Frontiers in Immunology

Volumn 9, Issue OCT, 2018, Pages

  Vitetta, Luis ^a,b   Vitetta, Gemma ^b   Hall, Sean ^b  

^a University of Sydney   (Australia)

^b Medlab   (Australia)

Author keywords

Bacteriophages; Bifidobacteria; Immunological tolerance; Inflammation; Lactobacilli; Prebiotics; Probiotics

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIOPHAGE; BACTERIUM; CLASSIFICATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INTESTINE; INTESTINE FLORA; MICROBIOLOGY; SYMBIOSIS; VIROLOGY;

BACTERIA; BACTERIOPHAGES; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNE TOLERANCE; INTESTINES; PREBIOTICS; PROBIOTICS; SYMBIOSIS;

EID: 85055251924     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02240     Document Type: Review

References (202)

1. Gest H. The discovery of microorganisms by Robert Hooke and Antoni Van Leeuwenhoek, fellows of the Royal Society. Notes Rec R Soc Lond. (2004) 58:187-201. doi:10.1098/rsnr.2004.0055.
2. Lewis KL, Reizis B. Dendritic cells: Arbiters of immunity and immunological tolerance. Cold Spring Harbor Perspect Biol. (2012) 4:a007401.
3. Probst HC, Muth S, Schild H. Regulation of the tolerogenic function of steady-state DCs. Eur J Immunol. (2014) 44:927-33. doi:10.1002/eji.201343862.
4. Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, et al. The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther. (2002) 16:1383-93. doi:10.1046/j.1365-2036.2002.01310.x.
5. Tissier H. Le bacterium coli et la reaction chromophile d'Escherich. Crit Rev Soc Biol. (1899) 51:943-945.
6. Funkhouser LJ, Bordenstein SR. Mom knows best: The universality of maternal microbial transmission. PLoS Biol. (2013) 11:e1001631. doi:10.1371/journal.pbio.1001631.
7. Mackowiak PA. Recycling metchnikoff: Probiotics, the intestinal microbiome and the quest for long life. Front Pub Health (2013) 1:52. doi:10.3389/fpubh.2013.00052.
8. Tissier H. Traitement des infections intestinales par la methode de la flore bacterienne de l'intestin. Crit Rev Soc Biol. (1906) 60:359-361.
9. Kaufmann SH. Immunology's foundation: The 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. (2008) 9:705-12. doi:10.1038/ni0708-705.
10. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, Gomez Alcala A, et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS ONE (2010) 5:e11484. doi:10.1371/journal.pone.0011484.
11. Parkin J, Cohen B. An overview of the immune system. Lancet (2001) 357:1777-89.doi:10.1016/S0140-6736(00)04904-7.
12. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. (2000) 343:108-17. doi:10.1056/NEJM200007133430207.
13. Freeley S, Kemper C, Le Friec G. The "ins and outs" of complement-driven immune responses. Immunol Rev. (2016) 274:16-32. doi:10.1111/imr.12472.
14. Cong J, Zhang X. How human microbiome talks to health and disease. Eur J Clin Microbiol Infect Dis. (2018) 37:1595-601doi:10.1007/s10096-018-3263-1.
15. McDermott AJ, Huffnagle GB. The microbiome and regulation of mucosal immunity. Immunology (2014) 142:24-31. doi:10.1111/imm.12231.
16. Vitetta L, Hall S, Linnane AW. Live probiotic cultures and the gastrointestinal tract: Symbiotic preservation of tolerance whilst attenuating pathogenicity. Front Cell Infect Microbiol. (2014) 4:143. doi:10.3389/fcimb.2014.00143.
17. Vitetta L, Saltzman ET, Thomsen M, Nikov T, Hall S. Adjuvant probiotics and the intestinal microbiome: Enhancing vaccines and immunotherapy outcomes. Vaccines (2017) 5: E50. doi:10.3390/vaccines5040050.
18. Hooks KB, O'Malley MA. Dysbiosis and its discontents. MBio (2017) 8:e01492-17. doi:10.1128/mBio.01492-17.
19. Haenel H. Some rules in the ecology of the intestinal microflora of man. J Appl Bacteriol. (1961) 24:242-51.
20. Stecher B, Maier L, Hardt WD. 'Blooming' in the gut: How dysbiosis might contribute to pathogen evolution. Nat Revi Microbiol. (2013) 11:277-84. doi:10.1038/nrmicro2989.
21. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature (2011) 473:174-80. doi:10.1038/nature09944.
22. Costea PI, Hildebrand F, Arumugam M, Backhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol. (2018) 3:8-16. doi:10.1038/s41564-017-0072-8.
23. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature (2006) 444:1022-3. doi:10.1101/cshperspect.a007401.
24. Srikanth CV, McCormick BA. Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: A three-way crosstalk. Interdisc Perspect Infect Dis. (2008) 2008:626827. doi:10.1155/2008/626827.
25. Porter EM, Bevins CL, Ghosh D, Ganz T. The multifaceted Paneth cell. Cell Mol Life Scie. (2002) 59:156-70. doi:10.1007/s00018-002-8412-z.
26. Tan DW, Barker N. Intestinal stem cells and their defining niche. Curr Top Develop Biol. (2014) 107:77-107. doi:10.1016/B978-0-12-416022-4.00003-2.
27. Rumio C, Sommariva M, Sfondrini L, Palazzo M, Morelli D, Vigano L, et al. Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. J Cell Physiol. (2012) 227:1107-13. doi:10.1002/jcp.22830.
28. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science (2001) 292:1115-8. doi:10.1126/science.1058709.
29. Peterson DA, Planer JD, Guruge JL, Xue L, Downey-Virgin W, Goodman AL, et al. Characterizing the interactions between a naturally primed immunoglobulin A and its conserved Bacteroides thetaiotaomicron species-specific epitope in gnotobiotic mice. J Biol Chem. (2015) 290:12630-49. doi:10.1074/jbc.M114.633800.
30. Morhardt TL, Hayashi A, Kao JY, Kamada N. Regional control of regulatory immune cells in the intestine. Curr Pathobiol Rep. (2018) 6:29-34. doi:10.1007/s40139-018-0156-z.
31. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature (2009) 462:226-30. doi:10.1038/nature08529.
32. Kimura S. Molecular insights into the mechanisms of M-cell differentiation and transcytosis in the mucosa-associated lymphoid tissues. Anatom Sci Int. (2018) 93:23-34. doi:10.1007/s12565-017-0418-6.
33. Corr SC, Gahan CC, Hill C. M-cells: Origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol. (2008) 52:2-12. doi:10.1111/j.1574-695X.2007.00359.x.
34. Kulkarni N, Pathak M, Lal G. Role of chemokine receptors and intestinal epithelial cells in the mucosal inflammation and tolerance. J Leukoc Biol. (2017) 101:377-94. doi:10.1189/jlb.1RU0716-327R.
35. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. (2003) 3:331-41. doi:10.1038/nri1057.
36. Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol. (2001) 2:1004-9. doi:10.1038/ni1101-1004.
37. Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microb. (2013) 13:711-22. doi:10.1016/j.chom.2013.05.013.
38. Man AL, Gicheva N, Regoli M, Rowley G, De Cunto G, Wellner N, et al. CX3CR1+ Cell-mediated salmonella exclusion protects the intestinal mucosa during the initial stage of infection. J Immunol. (2017) 198:335-43. doi:10.4049/jimmunol.1502559.
39. Regoli M, Bertelli E, Gulisano M, Nicoletti C. The multifaceted personality of intestinal CX3CR1(+) macrophages. Trends Immunol. (2017) 38:879-87. doi:10.1016/j.it.2017.07.009.
40. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. (2011) 12:5-9. doi:10.1038/ni0111-5.
41. Atarashi K, Umesaki Y, Honda K. Microbiotal influence on T cell subset development. Sem Immunol. (2011) 23:146-53. doi:10.1016/j.smim.2011.01.010.
42. Hachimura S, Totsuka M, Hosono A. Immunomodulation by food: Impact on gut immunity and immune cell function. Biosci Biotechnol Biochem. (2018) 82:584-99. doi:10.1080/09168451.2018.1433017.
43. Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Ann Rev Immunol. (2017) 35:119-47. doi:10.1146/annurev-immunol-051116-052424.
44. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, Mulder I, Lan A, Bridonneau C, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity (2009) 31:677-89. doi:10.1016/j.immuni.2009.08.020.
45. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 455:808-12. doi:10.1038/nature07240.
46. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microb. (2008) 4:337-49. doi:10.1016/j.chom.2008.09.009.
47. Wu HJ, Ivanov, II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity (2010) 32:815-27. doi:10.1016/j.immuni.2010.06.001.
48. Abeles SR, Pride DT. Molecular bases and role of viruses in the human microbiome. J Mol Biol. (2014) 426:3892-906. doi:10.1016/j.jmb.2014.07.002.
49. Telesford KM, Yan W, Ochoa-Reparaz J, Pant A, Kircher C, Christy MA, et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microb. (2015) 6:234-42. doi:10.1080/19490976.2015.1056973.
50. Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal clostridia: Leading players in the maintenance of gut homeostasis. Gut Pathog. (2013) 5:23. doi:10.1186/1757-4749-5-23.
51. Donaldson GP, Ladinsky MS, Yu KB, Sanders JG, Yoo BB, Chou WC, et al. Gut microbiota utilize immunoglobulin A for mucosal colonization. Science (2018) 360:795-800. doi:10.1126/science.aaq0926.
52. Mohamadzadeh M, Olson S, Kalina WV, Ruthel G, Demmin GL, Warfield KL, et al. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci USA. (2005) 102:2880-5. doi:10.1073/pnas.0500098102.
53. Fink LN, Zeuthen LH, Ferlazzo G, Frokiaer H. Human antigen-presenting cells respond differently to gut-derived probiotic bacteria but mediate similar strain-dependent NK and T cell activation. FEMS Immunol Med Microbiol. (2007) 51:535-46. doi:10.1111/j.1574-695X.2007.00333.x.
54. Young SL, Simon MA, Baird MA, Tannock GW, Bibiloni R, Spencely K, et al. Bifidobacterial species differentially affect expression of cell surface markers and cytokines of dendritic cells harvested from cord blood. Clin Diagnost Lab Immunol. (2004) 11:686-90. doi:10.1128/CDLI.11.4.686-690.2004.
55. Zeuthen LH, Christensen HR, Frokiaer H. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria. Clin Vaccine Immunol. (2006) 13:365-75. doi:10.1128/CVI.13.3.365-375.2006.
56. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol. (2009) 44:26-46. doi:10.1007/s00535-008-2296-0.
57. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. (2005) 115:1260-7. doi:10.1016/j.jaci.2005.03.036.
58. Niers LE, Hoekstra MO, Timmerman HM, van Uden NO, de Graaf PM, Smits HH, et al. Selection of probiotic bacteria for prevention of allergic diseases: Immunomodulation of neonatal dendritic cells. Clin Exp Immunol. (2007) 149:344-52. doi:10.1111/j.1365-2249.2007.03421.x.
59. Niers LE, Timmerman HM, Rijkers GT, van Bleek GM, van Uden NO, Knol EF, et al. Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy (2005) 35:1481-9. doi:10.1111/j.1365-2222.2005.02375.x.
60. Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutrit. (2004) 80:1618-25. doi:10.1093/ajcn/80.6.1618.
61. Rigby RJ, Knight SC, Kamm MA, Stagg AJ. Production of interleukin (IL)-10 and IL-12 by murine colonic dendritic cells in response to microbial stimuli. Clin Exp Immunol. (2005) 139:245-56. doi:10.1111/j.1365-2249.2004.02674.x.
62. Weise C, Zhu Y, Ernst D, Kuhl AA, Worm M. Oral administration of Escherichia coli Nissle 1917 prevents allergen-induced dermatitis in mice. Exp Dermatol. (2011) 20:805-9. doi:10.1111/j.1600-0625.2011.01326.x.
63. Kim JY, Choi YO, Ji GE. Effect of oral probiotics (Bifidobacterium lactis AD011 and Lactobacillus acidophilus AD031) administration on ovalbumin-induced food allergy mouse model. J Microbiol Biotechnol. (2008) 18:1393-400.
64. So JS, Lee CG, Kwon HK, Yi HJ, Chae CS, Park JA, et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol. (2008) 46:172-80. doi:10.1016/j.molimm.2008.07.038.
65. Hacini-Rachinel F, Gheit H, Le Luduec JB, Dif F, Nancey S, Kaiserlian D. Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS ONE (2009) 4:e4903. doi:10.1371/journal.pone.0004903.
66. Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy (2007) 37:498-505. doi:10.1111/j.1365-2222.2006.02629.x.
67. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Critic Care Med. (2009) 179:186-93. doi:10.1164/rccm.200806-951OC.
68. Hoarau C, Lagaraine C, Martin L, Velge-Roussel F, Lebranchu Y. Supernatant of Bifidobacterium breve induces dendritic cell maturation, activation, and survival through a Toll-like receptor 2 pathway. J Allergy Clin Immunol. (2006) 117:696-702. doi:10.1016/j.jaci.2005.10.043.
69. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Critic Care Med. (2007) 175:561-569. doi:10.1164/rccm.200606-821OC.
70. Kim CH. Immune regulation by microbiome metabolites. Immunology (2018) 154:220-9. doi:10.1111/imm.12930.
71. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. (2016) 16:341-52. doi:10.1038/nri.2016.42.
72. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA. (2010) 107:454-9. doi:10.1073/pnas.0910307107.
73. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microb. (2016) 7:189-200. doi:10.1080/19490976.2015.1134082.
74. Hemalatha R, Ouwehand AC, Saarinen MT, Prasad UV, Swetha K, Bhaskar V. Effect of probiotic supplementation on total Lactobacilli, bifidobacteria and short chain fatty acids in 2-5-year-old children. Microb Ecol Health Dis. (2017) 28:1298340. doi:10.1080/16512235.2017.1298340.
75. Fuller R. Probiotics in man and animals. J Appl Bacteriol. (1989) 66:365-78.
76. Morelli L, Capurso L. FAO/WHO guidelines on probiotics: 10 years later. J Clin Gastroenterol. (2012) 46(Suppl.):S1-S2. doi:10.1097/MCG.0b013e318269fdd5.
77. Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sanchez B, Margolles A. Bifidobacteria and their health-promoting effects. Microbiol Spectr. (2017) 5. doi:10.1128/microbiolspec.BAD-0010-2016.
78. Insoft RM, Sanderson IR, Walker WA. Development of immune function in the intestine and its role in neonatal diseases. Pediatr Clin North Am. (1996) 43:551-71. doi:10.1016/S0031-3955(05)70420-X.
79. Nowak A, Paliwoda A, Blasiak J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Critic Rev Food Sci Nutr. (2018). doi:10.1080/10408398.2018.1494539.
80. Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in human health and diseases. Front Microbiol. (2018) 9:757. doi:10.3389/fmicb.2018.00757.
81. Christensen HR, Frokiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. (2002) 168:171-8. doi:10.4049/jimmunol.168.1.171.
82. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: Homeostasis and immunopathology. Nutrients (2013) 5:1869-912. doi:10.3390/nu5061869.
83. Llewellyn A, Foey A. Probiotic modulation of innate cell pathogen sensing and signaling events. Nutrients (2017) 9:E1156. doi:10.3390/nu9101156.
84. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, et al. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Ther Adv Gastroenterol. (2016) 9:463-472. doi:10.1177/1756283X16645055.
85. Goldin BR, Gorbach SL. Clinical indications for probiotics: An overview. Clin Infect Dis. (2008) 46(Suppl. 2):S96-S100; discussion: S144-51. doi:10.1086/523333.
86. Vanderhoof JA, Young RJ. The role of probiotics in the treatment of intestinal infections and inflammation. Curr Opin Gastroenterol. (2001) 17:58-62.
87. Vitetta L, Briskey D, Alford H, Hall S, Coulson S. Probiotics, prebiotics and the gastrointestinal tract in health and disease. Inflammopharmacology (2014) 22:135-54. doi:10.1007/s10787-014-0201-4.
88. Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastroint Pathophysiol. (2014) 5:550-9. doi:10.4291/wjgp.v5.i4.550.
89. Wasilewski A, Zielinska M, Storr M, Fichna J. Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm Bowel Dis. (2015) 21:1674-82. doi:10.1097/MIB.0000000000000364.
90. Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr. (2008) 88:1438-46. doi:10.3945/ajcn.2008.26242.
91. Depeint F, Tzortzis G, Vulevic J, I'Anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: A randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr. (2008) 87:785-91. doi:10.1093/ajcn/87.3.785.
92. Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U, Boehm G. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Archiv Dis Child. (2006) 91:814-9. doi:10.1136/adc.2006.098251.
93. de Moura PN, Rosario Filho NA. The use of prebiotics during the first year of life for atopy prevention and treatment. Immun Inflamm Dis. (2013) 1:63-9. doi:10.1002/iid3.8.
94. Bassaganya-Riera J, DiGuardo M, Viladomiu M, de Horna A, Sanchez S, Einerhand AW, et al. Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease. J Nutr. (2011) 141:1318-25. doi:10.3945/jn.111.139022.
95. Ye MB, Lim BO, Dietary pectin regulates the levels of inflammatory cytokines and immunoglobulins in interleukin-10 knockout mice. J Agric Food Chem. (2010) 58:11281-6. doi:10.1021/jf103262s.
96. Kumar R, Dhanda S. Mechanistic insight of probiotics derived anticancer pharmaceuticals: A road forward for cancer therapeutics. Nutr Cancer (2017) 69:375-80. doi:10.1080/01635581.2017.1267773.
97. Konstantinov SR, Kuipers EJ, Peppelenbosch MP. Functional genomic analyses of the gut microbiota for CRC screening. Nat Rev Gastroenterol Hepatol. (2013) 10:741-5. doi:10.1038/nrgastro.2013.178.
98. Capurso G, Marignani M, Delle Fave G. Probiotics and the incidence of colorectal cancer: when evidence is not evident. Digest Liver Dis. (2006) 38(Suppl. 2):S277-S82. doi:10.1016/S1590-8658(07)60010-3.
99. Pool-Zobel BL. Inulin-type fructans and reduction in colon cancer risk: Review of experimental and human data. Br J Nutr. (2005) 93(Suppl. 1):S73-S90. doi:10.1079/BJN20041349.
100. Antza C, Stabouli S, Kotsis V. Gut microbiota in kidney disease and hypertension. Pharmacol. Res. (2018) 130:198-203. doi:10.1016/j.phrs.2018.02.028.
101. He J, Zhang F, Han Y. Effect of probiotics on lipid profiles and blood pressure in patients with type 2 diabetes: A meta-analysis of RCTs. Medicine (2017) 96:e9166. doi:10.1097/MD.0000000000009166.
102. Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agreus L, et al. Systematic review: Probiotics in the management of lower gastrointestinal symptoms - An updated evidence-based international consensus. Aliment Pharmacol Ther. (2018) 47:1054-1070. doi:10.1111/apt.14539.
103. Sun L, Liu H, Jiang H, Wei M, Liang S, Wang M, et al. Macrophages are involved in gut bacterial translocation and reversed by lactobacillus in experimental uremia. Digest Dis Sci. (2016) 61:1534-44. doi:10.1007/s10620-015-3950-z.
104. Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochr Database Syst Rev. (2017) 12:Cd006095. doi:10.1002/14651858.CD006095.pub3.
105. Hassan H, Rompola M, Glaser AW, Kinsey SE, Phillips RS. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer (2018) 26:2503-9. doi:10.1007/s00520-018-4216-z.
106. Hojsak I, Fabiano V, Pop TL, Goulet O, Zuccotti GV, Cokugras FC, et al. Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. Acta Paediatr. (2018) 107:927-37. doi:10.1111/apa.14270.
107. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers-a systematic review. Eur J Pediatr (2018) 177:979-94. doi:10.1007/s00431-018-3167-1.
108. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients (2017) 9:1021. doi:10.3390/nu9091021.
109. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Int J Gen Med. (2016) 9:27-37. doi:10.2147/IJGM.S98280.
110. Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients-A systematic review and meta-analysis. Antibiotics (2017) 6:E21. doi:10.3390/antibiotics6040021.
111. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochr Database Syst Rev. (2015) Cd004827. doi:10.1002/14651858.CD004827.pub2.
112. Lomax AR, Calder PC. Probiotics, immune function, infection and inflammation: A review of the evidence from studies conducted in humans. Curr Pharmac Des. (2009) 15:1428-518. doi:10.1017/S0007114508055608.
113. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. (2015) 42:1149-57. doi:10.1111/apt.13404.
114. Abraham BP, Quigley EMM. Probiotics in inflammatory bowel disease. Gastroenterol Clin North Am. (2017) 46:769-82. doi:10.1016/j.gtc.2017.08.003.
115. Parker EA, Roy T, D'Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition (2018) 45:125-134.e11. doi:10.1016/j.nut.2017.06.024.
116. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol. (2003) 38:9-12. doi:10.1016/S0928-8244(03)00147-0.
117. Schiffrin EJ, Donnet A, Blum S. How can we impact the immune system with pre- And probiotics? Nestle nutrition workshop series. Clin Perform Program. (2005) 10:203-13; discussion: 213-7.
118. Oberhelman RA, Gilman RH, Sheen P, Taylor DN, Black RE, Cabrera L, et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr. (1999) 134:15-20. doi:10.1016/S0022-3476(99)70366-5.
119. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. (2011) 45(Suppl. ):S149-53. doi:10.1097/MCG.0b013e3182257e98.
120. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. (2001) 138:361-5. doi:10.1067/mpd.2001.111321.
121. Athalye-Jape G, Rao S, Patole S. Effects of probiotics on experimental necrotizing enterocolitis: A systematic review and meta-analysis. Pediatr Res. (2018) 83:16-22. doi:10.1038/pr.2017.218.
122. Robinson J. Cochrane in context: Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health (2014) 9:672-4. doi:10.1002/ebch.1977.
123. Sun J, Marwah G, Westgarth M, Buys N, Ellwood D, Gray PH. Effects of probiotics on necrotizing enterocolitis, sepsis, intraventricular hemorrhage, mortality, length of hospital stay, and weight gain in very preterm infants: A meta-analysis. Adv Nutr. (2017) 8:749-763. doi:10.3945/an.116.014605.
124. Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: Novel insights into molecular targets and interventions using prebiotics. Benef Microb. (2014) 5:3-17. doi:10.3920/BM2012.0065.
125. Corzo N, Alonso JL, Azpiroz F, Calvo MA, Cirici M, Leis R, et al. Prebiotics: Concept, properties and beneficial effects. Nutricion Hospital. (2015) 31(Suppl. 1):99-118. doi:10.3305/nh.2015.31.sup1.8715.
126. Nawaz A, Bakhsh Javaid A, Irshad S, Hoseinifar SH, Xiong H. The functionality of prebiotics as immunostimulant: Evidences from trials on terrestrial and aquatic animals. Fish Shellf Immunol. (2018) 76:272-8. doi:10.1016/j.fsi.2018.03.004.
127. Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol. (2013) 4:445. doi:10.3389/fimmu.2013.00445.
128. Le Doare K, Holder B, Bassett A, Pannaraj PS. Mother's milk: A purposeful contribution to the development of the infant microbiota and immunity. Front Immunol. (2018) 9:361doi:10.3389/fimmu.2018.00361.
129. Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microb. (2017) 8:172-84. doi:10.1080/19490976.2017.1290756.
130. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. (2017) 14:491-502. doi:10.1038/nrgastro.2017.75.
131. Blaut M. Relationship of prebiotics and food to intestinal microflora. Eur J Nutr. (2002) 41(Suppl. 1):I11-6. doi:10.1007/s00394-002-1102-7.
132. Gibson GR. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutrit. (1999) 129:1438s-41.
133. Manning TS, Gibson GR. Microbial-gut interactions in health and disease. Prebiotics (2004) 18:287-98. doi:10.1016/j.bpg.2003.10.008.
134. Goh YJ, Klaenhammer TR. Genetic mechanisms of prebiotic oligosaccharide metabolism in probiotic microbes. Annu Rev Food Sci Technol. (2015) 6:137-56. doi:10.1146/annurev-food-022814-015706.
135. Slavin J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients (2013) 5:1417-35. doi:10.3390/nu5041417.
136. Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev. (2015) 28:42-66. doi:10.1017/S0954422415000037.
137. Kolida S, Gibson GR. Prebiotic capacity of inulin-type fructans. J Nutr. (2007) 137:2503s-6. doi:10.1093/jn/137.11.2503S.
138. Roberfroid MB. Prebiotics: Preferential substrates for specific germs? Am J Clin Nutr. (2001) 73:406s-9. doi:10.1093/ajcn/73.2.406s.
139. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. The Journal of nutrition (1995) 125:1401-12.
140. van Zanten GC, Knudsen A, Roytio H, Forssten S, Lawther M, Blennow A, et al. The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon. PLoS One (2012) 7e47212. doi:10.1371/journal.pone.0047212.
141. Schley PD, Field CJ. The immune-enhancing effects of dietary fibres and prebiotics. Br J Nutr. (2002) 87(Suppl. 2) S221-30. doi:10.1079/BJNBJN/2002541.
142. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients (2011) 3:858-76. doi:10.3390/nu3100858.
143. Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, et al. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endot Res. (2000) 6:243-7. doi:10.1177/09680519000060030501.
144. Hodin R. Maintaining gut homeostasis: The butyrate-NF-kappaB connection. Gastroenterology (2000) 118:798-801. doi:10.1016/S0016-5085(00)70150-8.
145. Park JS, Lee EJ, Lee JC, Kim WK, Kim HS. Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol. (2007) 7:70-7. doi:10.1016/j.intimp.2006.08.015.
146. Menzel T, Luhrs H, Zirlik S, Schauber J, Kudlich T, Gerke T, et al. Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1. Inflamm Bowel Dis. (2004) 10:122-8. doi:10.1097/00054725-200403000-00010.
147. Bohmig GA, Krieger PM, Saemann MD, Wenhardt C, Pohanka E, Zlabinger GJ. n-butyrate downregulates the stimulatory function of peripheral blood-derived antigen-presenting cells: A potential mechanism for modulating T-cell responses by short-chain fatty acids. Immunology (1997) 92:234-43.
148. Asarat M, Apostolopoulos V, Vasiljevic T, Donkor O. Short-chain fatty acids regulate cytokines and Th17/Treg cells in human peripheral blood mononuclear cells in vitro. Immunol Investig. (2016) 45:205-22. doi:10.3109/08820139.2015.1122613.
149. Cox MA, Jackson J, Stanton M, Rojas-Triana A, Bober L, Laverty M, et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol. (2009) 15:5549-57. doi:10.3748/wjg.15.5549.
150. Wiemer AJ, Hegde S, Gumperz JE, Huttenlocher A. A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist. J Immunol. (2011) 187:3663-70. doi:10.4049/jimmunol.1100103.
151. Birrell MA, Maher SA, Dekkak B, Jones V, Wong S, Brook P, et al. Anti-inflammatory effects of PGE2 in the lung: Role of the EP4 receptor subtype. Thorax (2015) 70:740-7. doi:10.1136/thoraxjnl-2014-206592.
152. Tedelind S, Westberg F, Kjerrulf M, Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. World J Gastroenterol. (2007) 13:2826-32. doi:10.3748/wjg.v13.i20.2826.
153. Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. (2011) 22:849-55. doi:10.1016/j.jnutbio.2010.07.009.
154. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microb. (2012) 3:289-306. doi:10.4161/gmic.19897.
155. Porter NT, Martens EC. The critical roles of polysaccharides in gut microbial ecology and physiology. Ann Rev Microb. (2017) 71:349-69. doi:10.1146/annurev-micro-102215-095316.
156. Pool-Zobel BL, Sauer J. Overview of experimental data on reduction of colorectal cancer risk by inulin-type fructans. J Nutr. (2007) 137:2580s-84. doi:10.1093/jn/137.11.2580S.
157. Whisner CM, Castillo LF. Prebiotics, bone and mineral metabolism. Calcif Tissue Int. (2018) 102:443-479. doi:10.1007/s00223-017-0339-3.
158. Satchithanandam S, Cassidy MM, Kharroubi AT, Calvert RJ, Leeds AR, Vahouny GV. Alterations in rat intestinal mucin patterns following luminal infusion of acetylsalicylic acid and prostaglandin derivatives. Digest Dis Sci. (1990) 35:1518-27. doi:10.1007/BF01540570.
159. Rivera-Huerta M, Lizarraga-Grimes VL, Castro-Torres IG, Tinoco-Mendez M, Macias-Rosales L, Sanchez-Bartez F, et al. Functional effects of prebiotic fructans in colon cancer and calcium metabolism in animal models. BioMed Res Int. (2017) 2017:9758982. doi:10.1155/2017/9758982.
160. Ducatelle R, Eeckhaut V, Haesebrouck F, Van Immerseel F. A review on prebiotics and probiotics for the control of dysbiosis: Present status and future perspectives. Animal (2015) 9:43-8. doi:10.1017/S1751731114002584.
161. Floch MH. The role of prebiotics and probiotics in gastrointestinal disease. Gastroenterol Clin North Am. (2018) 47:179-91. doi:10.1016/j.gtc.2017.09.011.
162. Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr. (2009) 63:1277-89. doi:10.1038/ejcn.2009.64.
163. Shokryazdan P, Faseleh Jahromi M, Navidshad B, Liang JB. Effects of prebiotics on immune system and cytokine expression. Med Microbiol Immunol. (2017) 206:1-9. doi:10.1007/s00430-016-0481-y.
164. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, et al. Prebiotic effects: Metabolic and health benefits. Br J Nutr. (2010) 104(Suppl. 2):S1-S63. doi:10.1017/S0007114510003363.
165. Waligora-Dupriet AJ, Campeotto F, Nicolis I, Bonet A, Soulaines P, Dupont C, et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. Int J Food Microbiol. (2007) 113:108-13. doi:10.1016/j.ijfoodmicro.2006.07.009.
166. Ziegler E, Vanderhoof JA, Petschow B, Mitmesser SH, Stolz SI, Harris CL, et al. Term infants fed formula supplemented with selected blends of prebiotics grow normally and have soft stools similar to those reported for breast-fed infants. J Pediat Gastroenterol Nutrit. (2007) 44:359-64. doi:10.1097/MPG.0b013e31802fca8c.
167. Duggan C, Penny ME, Hibberd P, Gil A, Huapaya A, Cooper A, et al. Oligofructose-supplemented infant cereal: 2 randomized, blinded, community-based trials in Peruvian infants. Am J Clin Nutr. (2003) 77:937-42. doi:10.1093/ajcn/77.4.937.
168. Costabile A, Klinder A, Fava F, Napolitano A, Fogliano V, Leonard C, et al. Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: A double-blind, placebo-controlled, crossover study. Br J Nutr. (2008) 99:110-20. doi:10.1017/S0007114507793923.
169. Carvalho-Wells AL, Helmolz K, Nodet C, Molzer C, Leonard C, McKevith B, et al. Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: A human feeding study. Br J Nutr. (2010) 104:1353-6. doi:10.1017/S0007114510002084.
170. Sanz Y. Microbiome and gluten. Ann Nutr Metab (2015) 67(Suppl. 2):28-41. doi:10.1159/000440991.
171. Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, et al. The impact of the level of the intestinal short chain Fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. (2010) 4:53-8. doi:10.2174/1874091X01004010053.
172. Nicolucci AC, Hume MP, Martinez I, Mayengbam S, Walter J, Reimer RA. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology (2017) 153:711-22. doi:10.1053/j.gastro.2017.05.055.
173. Ho J, Reimer RA, Doulla M, Huang C. Effect of prebiotic intake on gut microbiota, intestinal permeability and glycemic control in children with type 1 diabetes: Study protocol for a randomized controlled trial. Trials 17 (2016):347. doi:10.1186/s13063-016-1486-y.
174. Krokowicz L, Kaczmarek BF, Krokowicz P, Stojcev Z, Mackiewicz J, Walkowiak J, et al. Sodium butyrate and short chain fatty acids in prevention of travellers' diarrhoea: A randomized prospective study. Travel Med Infect Dis. (2014) 12:183-8. doi:10.1016/j.tmaid.2013.08.008.
175. West NP, Pyne DB, Cripps AW, Christophersen CT, Conlon MA, Fricker PA. Gut Balance, a synbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individuals. Gut microbes (2012) 3:221-7. doi:10.4161/gmic.19579.
176. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut (2006) 55:348-55. doi:10.1136/gut.2005.074971.
177. Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. (2015) 114:586-95. doi:10.1017/S0007114515001889.
178. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut (2011) 60:923-9. doi:10.1136/gut.2010.232025.
179. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence (2014) 5:226-35. doi:10.4161/viru.25991.
180. Criscuolo E, Spadini S, Lamanna J, Ferro M, Burioni R. Bacteriophages and their immunological applications against infectious threats. J Immunol Res. (2017) 2017:3780697. doi:10.1155/2017/3780697.
181. Breitbart M, Rohwer F. Here a virus, there a virus, everywhere the same virus? Trends Microbiol. (2005) 13:278-84. doi:10.1016/j.tim.2005.04.003.
182. Carding SR, Davis N, Hoyles L. Review article: The human intestinal virome in health and disease. Aliment Pharmacol Ther. (2017) 46:800-15. doi:10.1111/apt.14280.
183. Kim MS, Park EJ, Roh SW, Bae JW. Diversity and abundance of single-stranded DNA viruses in human feces. Appl Environ Microbiol. (2011) 77:8062-70. doi:10.1128/AEM.06331-11.
184. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc Natl Acad Sci USA. (2016) 113:10400-5. doi:10.1073/pnas.1601060113.
185. Duerkop BA, Hooper LV. Resident viruses and their interactions with the immune system. Nat Immunol. (2013) 14:654-9. doi:10.1038/ni.2614.
186. Breitbart M, Hewson I, Felts B, Mahaffy JM, Nulton J, Salamon P, et al. Metagenomic analyses of an uncultured viral community from human feces. J Bacteriol. (2003) 185:6220-3. doi:10.1128/JB.185.20.6220-6223.2003.
187. Duranti S, Lugli GA, Mancabelli L, Armanini F, Turroni F, James K, et al. Maternal inheritance of bifidobacterial communities and bifidophages in infants through vertical transmission. Microbiome (2017) 5:66. doi:10.1186/s40168-017-0282-6.
188. Chhibber S, Bansal S, Kaur S. Disrupting the mixed-species biofilm of Klebsiella pneumoniae B5055 and Pseudomonas aeruginosa PAO using bacteriophages alone or in combination with xylitol. Microbiology (2015) 161:1369-77. doi:10.1099/mic.0.000104.
189. Gorski A, Miedzybrodzki R, Borysowski J, Dabrowska K, Wierzbicki P, Ohams M, et al. Phage as a modulator of immune responses: Practical implications for phage therapy. Adv Virus Res. (2012) 83:41-71. doi:10.1016/B978-0-12-394438-2.00002-5.
190. Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliano J, et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA. (2013) 110:10771-6. doi:10.1073/pnas.1305923110.
191. Barr JJ, Youle M, Rohwer F. Innate and acquired bacteriophage-mediated immunity. Bacteriophage (2013) 3:e25857. doi:10.4161/bact.25857.
192. Clark JR, March JB. Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol. (2006) 24:212-8. doi:10.1016/j.tibtech.2006.03.003.
193. Kurzepa A, Dabrowska K, Skaradzinski G, Gorski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med. (2009) 9:93-100. doi:10.1007/s10238-008-0027-8.
194. Molenaar TJ, Michon I, de Haas SA, van Berkel TJ, Kuiper J, Biessen EA. Uptake and processing of modified bacteriophage M13 in mice: Implications for phage display. Virology (2002) 293:182-91. doi:10.1006/viro.2001.1254.
195. Hill C, Mills S, Ross RP. Phages & antibiotic resistance: Are the most abundant entities on earth ready for a comeback? Future Microbiol. (2018) 13:711-26. doi:10.2217/fmb-2017-0261.
196. Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell (2015) 160:447-60. doi:10.1016/j.cell.2015.01.002.
197. Lucas Lopez R, Grande Burgos MJ, Galvez A, Perez Pulido R. The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: A state of the science review. APMIS (2017) 125:3-10. doi:10.1111/apm.12609.
198. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: Comparison with commensals and pathogens. Nat Rev Microbiol. (2010) 8:171-84. doi:10.1038/nrmicro2297.
199. Konieczna P, Akdis CA, Quigley EM, Shanahan F, O'Mahony L. Portrait of an immunoregulatory Bifidobacterium. Gut Microb. (2012) 3:261-6. doi:10.4161/gmic.20358.
200. Laino J, Villena J, Kanmani P, Kitazawa H. Immunoregulatory effects triggered by lactic acid bacteria exopolysaccharides: New insights into molecular interactions with host cells. Microorganisms (2016) 4:E27. doi:10.3390/microorganisms403002.
201. Dwivedi M, Kumar P, Laddha NC, Kemp EH. Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev. (2016) 15:379-92. doi:10.1016/j.autrev.2016.01.002.
202. Gerhauser C. Impact of dietary gut microbial metabolites on the epigenome. Philosoph Transac R Soc Lond Ser B Biol Sci. (2018) 373: 20170359. doi:10.1098/rstb.2017.0359.